FLEETCOR® Acquires Plugsurfing, a Leading European Electric Vehicle Solutions Provider
14.9.2022 16:26:00 EEST | Business Wire | Press release
FLEETCOR Technologies, Inc. (NYSE: FLT), a leading global business payments company, announced today the acquisition of Plugsurfing, a leading European electric vehicle (EV) software and network provider to vehicle OEMs, charge point operators (CPO), and fleets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220831005602/en/
“The acquisition demonstrates FLEETCOR®’s commitment to developing world-class EV solutions for our thousands of commercial fleet customers, including access to European EV roaming capabilities and software applications for drivers and fleet managers,” said Tom Rowlands, global managing director of EV at FLEETCOR. “In addition, Plugsurfing allows us to pursue new customer segments by serving CPOs with software to manage their charging infrastructure and providing OEMs with a white-label EV solution. We’re excited to have Plugsurfing join the FLEETCOR family.”
Plugsurfing has developed a proprietary EV charging network in Europe with over 300,000 charge points, or nearly 80% of all charge points in Europe. The Plugsurfing app provides access to comprehensive tariff information and facilitates payment for EV charging. This capability is an essential tool for EV drivers and is available directly and as a turnkey white-label solution to EV OEMs for distribution to their customers.
In addition, Plugsurfing also serves CPOs with API, cloud-based operating software that enables CPOs to run their hardware efficiently and effectively, including managing payments of charging events.
Since its founding in 2012, Plugsurfing has processed about 20 million charging sessions and has been at the forefront of consolidating and simplifying the European EV ecosystem.
“We’re thrilled to bring a boost to the electric future in Europe through our acquisition by FLEETCOR. With their distribution and resources, we can scale our Plugsurfing platform to better serve existing and future customers on the EV journey that will continue to evolve over time. We’re excited about the prospects for continuing to help usher in an EV future,” Tatu Kulla, chief executive officer at Plugsurfing.
About FLEETCOR®
FLEETCOR Technologies (NYSE: FLT) is a leading global corporate payments company that helps businesses spend less by providing innovative solutions that enable and control expense-related purchasing and payment processes. The FLEETCOR portfolio of brands automate, secure, digitize and manage payment transactions on behalf of businesses across more than 100 countries in North America, Latin America, Europe, and Asia Pacific. For more information, please visit www.FLEETCOR.com.
About Plugsurfing
Plugsurfing aligns the entire car charging ecosystem—drivers, charging point operators, and carmakers—within a single platform. The over one million drivers connected to our platform benefit from a network of over 300,000 charging points across Europe and a reliable experience through our app or solutions designed for our partners. We serve charging point operators with a back-end cloud software for managing everything from country-specific regulations to providing diverse payment options for customers. Carmakers benefit from white label solutions as well as deeper integrations with their in-house technology. For more information, please visit www.plugsurfing.com.
###
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005602/en/
Contact information
Scott Girling-Heathcote, SkyParlour
scott@skyparlour.com
+44 (0)330 043 1315
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom